| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1038732520 |
| P356 | DOI | 10.2165/00003088-199325040-00003 |
| P698 | PubMed publication ID | 8261712 |
| P2093 | author name string | R J MacFadyen | |
| H L Elliott | |||
| P A Meredith | |||
| P2860 | cites work | A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure | Q28328342 |
| Ramipril prevents left ventricular hypertrophy with myocardial fibrosis without blood pressure reduction: a one year study in rats | Q33189269 | ||
| Age and the pharmacokinetics of angiotensin converting enzyme inhibitors enalapril and enalaprilat | Q34447399 | ||
| Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators | Q34539986 | ||
| Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure | Q34620874 | ||
| Plasma enalapril levels and hormonal effects after short- and long-term administration in essential hypertension | Q34621390 | ||
| Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). | Q34682919 | ||
| Factors related to first dose hypotensive effect of captopril: prediction and treatment. | Q34991422 | ||
| Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension | Q35316601 | ||
| Concentration-effect analysis of antihypertensive drug responses | Q37939087 | ||
| Angiotensin-converting enzyme: new concepts concerning its biological role | Q38206789 | ||
| The effects of frusemide and angiotensin-converting enzyme inhibitors and their combination on cardiac and renal haemodynamics in heart failure | Q39189211 | ||
| An overview of the clinical pharmacology of enalapril | Q40080622 | ||
| Studies with low dose intravenous diacid ACE inhibitor (perindoprilat) infusions in normotensive male volunteers | Q41952564 | ||
| The pharmacokinetics of enalapril in patients with compensated liver cirrhosis | Q42229384 | ||
| Enalapril maleate and a lysine analogue (MK-521): disposition in man | Q42264743 | ||
| Enalapril (MK421) activation in man: importance of liver status | Q42530755 | ||
| The pharmacokinetics of enalapril in hospitalized patients with congestive heart failure | Q42652405 | ||
| Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions | Q43472007 | ||
| Pharmacokinetics of the converting enzyme inhibitor cilazapril in normal volunteers and the relationship to enzyme inhibition: development of a mathematical model | Q43474193 | ||
| Pharmacokinetics of an ACE inhibitor, S-9780, in man: evidence of tissue binding | Q43589843 | ||
| Prediction of the antihypertensive response to enalapril | Q44667668 | ||
| Furosemide-induced natriuresis is augmented by ultra-low-dose captopril but not by standard doses of captopril in chronic heart failure | Q46357646 | ||
| Influence of Food on the Bioavailability of Enalapril | Q51640991 | ||
| Enalapril maleate (MK-421), a potent, nonsulfhydryl angiotensin-converting enzyme inhibitor: absorption, disposition, and metabolism in man | Q67284916 | ||
| Circulating angiotensin II levels under repeated administration of lisinopril in normal subjects | Q67503653 | ||
| Pharmacokinetics and converting enzyme inhibition after morning and evening administration of oral enalapril to healthy subjects | Q68242802 | ||
| Kinetic-dynamic relations and individual responses to enalapril | Q68448931 | ||
| Determinants of angiotensin II generation during converting enzyme inhibition | Q68483629 | ||
| Pharmacokinetics and pharmacodynamics of enalapril in patients with congestive heart failure and patients with hypertension | Q68938377 | ||
| Kinetics and dynamics of enalapril in patients with liver cirrhosis | Q69350436 | ||
| Pharmacokinetics of enalapril and lisinopril in subjects with normal and impaired hepatic function | Q69356123 | ||
| Enalapril pharmacokinetics in diabetic patients | Q69367117 | ||
| Captopril and the diuretic requirements in moderate and severe chronic heart failure | Q69530027 | ||
| Angiotensin-Converting Enzyme Inhibition Does Not Suppress Plasma Angiotensin II Increase During Exercise in Humans | Q72069444 | ||
| Enalapril Worldwide Experience | Q72391946 | ||
| Pharmacokinetics of repeated single oral doses of enalapril maleate (mk-421) in normal volunteers | Q72396519 | ||
| Clinical pharmacology of enalapril | Q72417030 | ||
| P433 | issue | 4 | |
| P921 | main subject | pharmacodynamics | Q725307 |
| pharmacokinetics | Q323936 | ||
| enalapril | Q422185 | ||
| P304 | page(s) | 274-282 | |
| P577 | publication date | 1993-10-01 | |
| P1433 | published in | Clinical Pharmacokinetics | Q5133788 |
| P1476 | title | Enalapril clinical pharmacokinetics and pharmacokinetic-pharmacodynamic relationships. An overview | |
| P478 | volume | 25 |
| Q36595721 | A detailed physiologically based model to simulate the pharmacokinetics and hormonal pharmacodynamics of enalapril on the circulating endocrine Renin-Angiotensin-aldosterone system |
| Q44277073 | ABPM comparison of the anti-hypertensive profiles of telmisartan and enalapril in patients with mild-to-moderate essential hypertension |
| Q51313450 | Bioequivalence of enalapril oral solution for treatment of pediatric hypertension and enalapril tablets. |
| Q38824081 | Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Enalapril |
| Q47913024 | Clinical pharmacokinetics of vasodilators. Part I. |
| Q44091853 | Determination of enalapril and enalaprilat by enzyme linked immunosorbent assays: application to pharmacokinetic and pharmacodynamic analysis |
| Q71485703 | Dose-dependent pharmacokinetics of warfarin in healthy volunteers |
| Q33175327 | Drug-induced orthostatic hypotension in the elderly: avoiding its onset |
| Q36243667 | Effect of carboxylesterase 1 c.428G > A single nucleotide variation on the pharmacokinetics of quinapril and enalapril |
| Q37356592 | Endogenous production of angiotensin II modulates rat proximal tubule transport |
| Q73120415 | Enhancing paracellular permeability by modulating epithelial tight junctions |
| Q36053876 | Evaluation of the angiotensin challenge methodology for assessing the pharmacodynamic profile of antihypertensive drugs acting on the renin-angiotensin system |
| Q39055030 | Intravenous enalaprilat for treatment of acute hypertensive heart failure in the emergency department |
| Q41333137 | Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists. |
| Q88317476 | Projecting ADME Behavior and Drug-Drug Interactions in Early Discovery and Development: Application of the Extended Clearance Classification System |
| Q83460719 | Rapid and sensitive liquid chromatography/tandem mass spectrometry method for simultaneous determination of enalapril and its major metabolite enalaprilat, in human plasma: application to a bioequivalence study |
| Q92612804 | Relative Bioavailability of Enalapril Administered as Orodispersible Minitablets in Healthy Adults |
| Q37851883 | The management of hypertensive emergencies in children after stem cell transplantation |
| Q64101852 | The renin-angiotensin-aldosterone system and its suppression |
| Q35014556 | Treatment of hypertension with an angiotensin II-receptor antagonist compared with an angiotensin-converting enzyme inhibitor: a review of clinical studies of telmisartan and enalapril |
| Q36851934 | Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions |
Search more.